David H. Ilson, MD, PhD 
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an MD, PhD combined degree program at New York University and received a Master’s degree and PhD in Basic Science and an MD from New York University. He completed his internship and residency in Internal Medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in Medical Oncology and Hematology, including a third-year fellowship as the Brian Piccolo research fellow.

Dr. Ilson joined the staff at MSKCC in 1992, becoming a member of the GI Oncology Service in the Department of Medicine. He was a recipient of an American Cancer Society Career Development Award. Dr. Ilson is now an attending physician and member at Memorial Hospital and is Professor of Medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. Dr. Ilson is a nationally recognized authority in the treatment of gastrointestinal cancer. His research has focused on the study of new agents in advanced esophageal cancer and on the evaluation of novel agents in combined modality therapy programs in locally advanced disease. Dr. Ilson sits on the GI committees of Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG) as well as the Upper GI Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN). He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee. Dr. Ilson currently chairs or co-chairs several national clinical trials in esophageal cancer. Dr. Ilson has been writing for NEJM Journal Watch Oncology and Hematology since 2006.

Yelena Y. Janjigian, MD
Associate Professor and Chief, Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
                           New York, NY

Dr. Janjigian’s clinical practice and research are focused on improving treatment outcomes for people with esophageal and stomach cancers. She has vast experience working with translational biomarker studies leading both investigator initiated and large multicenter registration trials, as well as early phase clinical trials and is a leader in the field. 

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
David H. Ilson, MD, PhD—has disclosed that he is a consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, and Roche.
Susan H. Gitzinger, PharmD, MPA—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
David H. Ilson, MD, PhD—has disclosed that he is a consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, and Roche.
Yelena Y. Janjigian, MD—has disclosed that she is a consultant for AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Imugene, Merck, Merck Serono, Pfizer, RGENIX, Seattle Genetics, and Zymeworks. She receives grant/research support from Bayer, Bristol Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred's Team, Genentech/Roche, Merck, NCI, and RGENIX. She also receives other financial or material support from RGENIX.

Peer Reviewers:
Allison Butts, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Efrat Dotan, MD—has disclosed that she is a consultant for Basilea and QED. She receives grant/research support from AstraZeneca, Incyte, Ipsen, Lilly, Medimmune, and SDP oncology.